The morcellation controversy heats up as physicians all over the world who use Ethicon power morcellators are being asked to return the medical devices.
Earlier this year, Johnson & Johnson’s Ethicon unit suspended sales and distribution of its power morcellators. J&J is now calling for “a worldwide market withdrawal” of any Ethicon morcellation devices, and they are asking their customers-physicians and hospitals-to return any and all of these devices that have already been purchased. The company is issuing a credit for all devices returned before December 30, 2014. (
to see the letter.)
J&J’s decision comes after the FDA has recommended that the use of these devices be suspended until further review of the risk of these devices inadvertently spreading an unknown cancer in women with fibroids.
"Due to this continued uncertainty, Ethicon believes that a market withdrawal of Ethicon morcellation devices is the appropriate course of action at this time until further medical guidelines are established and/or new technologies are developed to mitigate the risk," the company said in an e-mailed statement to Reuters, as reported in this Huffington Post article.
How will this impact your practice, and what do you think about this recall?
(We invite you to share your thoughts in the Comment Section below.)
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Dysmenorrhea management via telemedicine vs. in-person visits only
March 12th 2024Investigating dysmenorrhea outcomes with low-dose pill prescriptions reveals no significant difference between combination telemedicine and in-person consultations vs in-person only, prompting further exploration into telemedicine's role in gynecological care.
Read More